多西环素联合阿奇霉素治疗恙虫病合并肺部感染的效果与安全性评价

Efficacy and Safety of Doxycycline Combined with Azithromycin in the Treatment of Tsutsugamushi Disease Complicated with Pulmonary Infection

目的:探讨多西环素联合阿奇霉素治疗恙虫病合并肺部感染的效果与安全性。方法:选择2019年7月—2022年7月莆田市第一医院收治的150例恙虫病合并肺部感染患者作为观察对象。根据治疗方法差异性分为两组,各75例。对照组使用多西环素,观察组在对照组基础上联合阿奇霉素治疗。比较两组的治疗效果和安全性。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组肺部湿啰音消失时间、肝功能恢复时间、焦痂脱落时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率高于对照组,差异有统计学意义(P<0.05)。结论:多西环素联合阿奇霉素治疗恙虫病合并肺部感染,能有效提高患者整体治疗效果,加快症状消失进度,但是联合用药有较高不良反应,治疗安全性低于单一用药。

Objective:To explore the efficacy and safety of Doxycycline combined with Azithromycin in the treatment of tsutsugamushi disease complicated with pulmonary infection.Method:A total of 150 patients with Tsutsugamushi disease complicated with pulmonary infection admitted to the First Hospital of Putian City from July 2019 to July 2022 were selected as the observation objects.According to the difference of treatment methods,they were divided into two groups,with 75 cases in each group.The control group was treated with Doxycycline,and the observation group was treated with Azithromycin based on the control group.The therapeutic effect and safety of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The disappearance time of lung moist rales,liver function recovery time,eschar shedding time and hospital stay in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in observation group was higher than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Doxycycline combined with Azithromycin can effectively improve the overall therapeutic effect and accelerate the progress of symptom disappearance in the treatment of tsutsugamushi disease complicated with pulmonary infection,but the combination has higher adverse reactions and the safety of treatment is lower than that of single drug.